CycloSam® Sm-153 DOTMP Spun-Out into IGL Pharma, Inc.

A new company, IGL Pharma, Inc. has been formed to move CycloSam® forward through clinical trials. CycloSam® is a patented new bone-seeking radiopharmaceutical being developed for bone cancers, including the treatment of primary bone tumors, secondary bone metastases and for bone marrow ablation/transplant.


Brachytherapy Treatment for Solid Tumors

IsoTherapeutics, in collaboration with the Gabriel Institute and Valco Instruments Company, Inc. has developed a novel patented method to treat solid inoperable tumors. Traditional brachytherapy uses encapsulated gamma emitters which makes irradiation of non-target tissue a potential issue. Beta emitters, which would have a much smaller field of irradiation, are generally not used in this manner because the capsules would effectively shield the beta particles. Use of beta emitters without encapsulation would normally result in the migration of isotope and thus radiation dose to non-target tissues. BetaBrach™ involves a simple and effective chemical approach to immobilizing metallic radioisotopes. This technology is available for license.

Got a Project? Let's Schedule An Appointment

The IsoTherapeutics Group will be at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Chicago June 24-27.
We value our relationship with you and your organization, and we would be pleased to spend some time discussing the latest developments in our industry and explore how we may be able to assist you.
Please feel free to drop by our exhibition booth (#4094) if you have a chance. If you would like to schedule some time for more in-depth discussions, feel free to give me a call or send me an e-mail, and we can try to work out something that suits both of our schedules.
We hope to see you at the meeting.